Tenon Medical (TNON) Q2 2024 earnings summary

Executive summary

• Achieved 21% year-over-year revenue growth in Q2 2024 to $901,000, driven by increased adoption of the Catamaran system and a restructured sales and marketing strategy.

• Net loss for Q2 2024 narrowed to $3.8 million from $4.3 million in Q2 2023, reflecting improved gross margin and reduced operating expenses.

• Gross profit for Q2 2024 was $470,000 (52% margin), up 142% from $194,000 (26% margin) in Q2 2023.

• Expanded operational reach to five U.S. sales regions, fully resourced for future growth.

• CFO transition announced, with Jay Hansen appointed interim Principal Accounting Officer.

Financial highlights

• Q2 2024 revenue was $901,000, up 21% from $743,000 in Q2 2023; six-month revenue rose 38% year-over-year to $1.6 million.

• Gross margin for Q2 2024 was 52% (up from 26% in Q2 2023); six-month gross margin was 58%.

• Operating expenses for Q2 2024 were $4.3 million, slightly down from $4.5 million in Q2 2023.

• Net loss for Q2 2024 was $3.8 million; six-month net loss was $7.4 million, improved from $9.1 million in 2023.

• Cash and cash equivalents totaled $2 million as of June 30, 2024; no outstanding debt.

Outlook and guidance

• Expectation of continued operating losses and negative cash flows as commercialization and product development continue.

• Existing cash is insufficient to fund operations for the next 12 months; additional capital will be sought via equity, debt, or collaborations.

• Upcoming publication of interim clinical study data and near completion of study enrollment expected to drive further adoption.

• Anticipate ongoing expansion of physician workshops and commercial infrastructure.

• Substantial doubt exists regarding the company's ability to continue as a going concern over the next year.